Cathay Biotech Inc.

SHSE:688065 Voorraadrapport

Marktkapitalisatie: CN¥27.1b

Cathay Biotech Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Cathay Biotech's earnings have been declining at an average annual rate of -4%, while the Chemicals industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 9.4% per year. Cathay Biotech's return on equity is 2.6%, and it has net margins of 14.4%.

Belangrijke informatie

-4.0%

Groei van de winst

-6.6%

Groei van de winst per aandeel

Chemicals Groei van de industrie12.1%
Inkomstengroei9.4%
Rendement op eigen vermogen2.6%
Nettomarge14.4%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

We Think That There Are More Issues For Cathay Biotech (SHSE:688065) Than Just Sluggish Earnings

May 06
We Think That There Are More Issues For Cathay Biotech (SHSE:688065) Than Just Sluggish Earnings

Recent updates

What Cathay Biotech Inc.'s (SHSE:688065) 38% Share Price Gain Is Not Telling You

Oct 22
What Cathay Biotech Inc.'s (SHSE:688065) 38% Share Price Gain Is Not Telling You

Cathay Biotech (SHSE:688065) Could Be Struggling To Allocate Capital

Oct 20
Cathay Biotech (SHSE:688065) Could Be Struggling To Allocate Capital

Cathay Biotech (SHSE:688065) Seems To Use Debt Quite Sensibly

Sep 29
Cathay Biotech (SHSE:688065) Seems To Use Debt Quite Sensibly

Cathay Biotech Inc.'s (SHSE:688065) Share Price Not Quite Adding Up

Sep 07
Cathay Biotech Inc.'s (SHSE:688065) Share Price Not Quite Adding Up

There Are Reasons To Feel Uneasy About Cathay Biotech's (SHSE:688065) Returns On Capital

Jun 19
There Are Reasons To Feel Uneasy About Cathay Biotech's (SHSE:688065) Returns On Capital

Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance Sheet

May 28
Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance Sheet

What Cathay Biotech Inc.'s (SHSE:688065) 27% Share Price Gain Is Not Telling You

May 07
What Cathay Biotech Inc.'s (SHSE:688065) 27% Share Price Gain Is Not Telling You

We Think That There Are More Issues For Cathay Biotech (SHSE:688065) Than Just Sluggish Earnings

May 06
We Think That There Are More Issues For Cathay Biotech (SHSE:688065) Than Just Sluggish Earnings

Opbrengsten en kosten

Hoe Cathay Biotech geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

SHSE:688065 Opbrengsten, kosten en inkomsten (CNY Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 242,764398238232
30 Jun 242,528372227203
31 Mar 242,293414198184
31 Dec 232,114367215189
30 Sep 232,169381235179
30 Jun 232,183459256187
31 Mar 232,285436270199
31 Dec 222,441553239188
30 Sep 222,447605207184
30 Jun 222,517619188164
31 Mar 222,538628182145
31 Dec 212,363595181134
30 Sep 212,099612143118
30 Jun 211,83956414799
31 Mar 211,57948114497
31 Dec 201,49745814684
30 Sep 201,48242818170
30 Jun 201,60143220341
31 Mar 201,722475258105
31 Dec 191,91647921290
31 Dec 181,75746618586
31 Dec 171,36333313165
31 Dec 1692914510538

Kwaliteitswinsten: 688065 has high quality earnings.

Groeiende winstmarge: 688065's current net profit margins (14.4%) are lower than last year (17.6%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 688065's earnings have declined by 4% per year over the past 5 years.

Versnelling van de groei: 688065's earnings growth over the past year (4.4%) exceeds its 5-year average (-4% per year).

Winst versus industrie: 688065 earnings growth over the past year (4.4%) exceeded the Chemicals industry -3.8%.

Rendement op eigen vermogen

Hoge ROE: 688065's Return on Equity (2.6%) is considered low.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y